Literature DB >> 16136200

Chemotherapy-induced hypersensitivity reactions.

Barbara Holmes Gobel1.   

Abstract

PURPOSE/
OBJECTIVES: To assist clinical nurses in understanding the complex nature of chemotherapy-induced hypersensitivity reactions as well as effectively preventing or managing these reactions. DATA SOURCES: Published articles and abstracts, pertinent book chapters, computerized databases. DATA SYNTHESIS: Most available chemotherapy drugs can cause hypersensitivity reactions, but certain drug groups frequently are associated with these reactions (e.g., asparaginases, taxanes, platinum compounds, epipodophyllotoxins). Preventing hypersensitivity reactions is the primary goal; however, understanding the principles of managing these reactions is critical because hypersensitivity reactions can occur despite using appropriate prevention strategies.
CONCLUSIONS: Chemotherapy-induced hypersensitivity reactions are potentially life-threatening. Nurses working with chemotherapy drugs must understand which drugs are associated with a high risk of causing hypersensitivity reactions and must be prepared to attempt to prevent or manage reactions. IMPLICATIONS FOR NURSING: The potentially life-threatening nature of hypersensitivity reactions to chemotherapy requires that nurses have a plan to manage them. This may include a written policy on staff education and training, appropriate equipment, and medications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136200     DOI: 10.1188/05.onf.1027-1035

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  2 in total

1.  Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.

Authors:  Simbarashe Takuva; Shelly T Karuna; Michal Juraska; Erika Rudnicki; Srilatha Edupuganti; Maija Anderson; Robert De La Grecca; Martin R Gaudinski; Alice Sehurutshi; Catherine Orrell; Logashvari Naidoo; Javier Valencia; Larissa M Villela; Stephen R Walsh; Philip Andrew; Carissa Karg; April Randhawa; John Hural; Margarita M Gomez Lorenzo; David N Burns; Julie Ledgerwood; John R Mascola; Myron Cohen; Lawrence Corey; Kathy Mngadi; Nyaradzo M Mgodi
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-01       Impact factor: 3.771

2.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.